PRGN-2009, a viral vector targeting HPV16/18, alone or in combination with BA, a bifunctional TGF-β “trap”/anti-PD-L1 fusion protein, was well tolerated and showed encouraging activity in patients with HPV-associated cancers. This evidence concerns the gene CD274 and cancer.